- Home
- FOXX vs VCEL Comparison
FOXX vs VCEL Comparison
Compare FOXX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | VCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | FOXX | VCEL |
|---|---|---|
| Price | $4.11 | $36.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | 34.6K | ★ 586.8K |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | $63,030,415.00 | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $151.65 |
| Revenue Growth | ★ 139.29 | 14.05 |
| 52 Week Low | $1.71 | $29.24 |
| 52 Week High | $11.00 | $63.00 |
Technical Indicators
Market Signals| Indicator | FOXX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 45.04 |
| Support Level | $4.00 | $35.99 |
| Resistance Level | $4.34 | $39.07 |
| Average True Range (ATR) | 0.37 | 1.76 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 38.30 | 16.46 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.